2025-04-30 20:48:49
Latest Post
Monarch Networth Capital IFSC Pvt. Ltd. receives Registered Fund Management Entity (Retail) License from IFSCA, GIFT City
Lucent Industries Ltd enters into partnership agreement with Clusterdev Technologies Pvt Ltd
South Indian Bank hosts Season 1 of National Co-lending Summit - SEED
Inox Green signs agreement for O&M of 675 MWp of solar projects
Union Bank of India Launches MSME & CASA Outreach Programs to pass on benefits of back to back RBI-MPC rate cuts and Deepen Customer Engagement
Stock Report
Nath Bio-Genes India Ltd Q4 FY25 consolidated net profit slips to Rs. 1.48 crore
Posted On : 2025-04-29 21:08:54( TIMEZONE : IST )
Nath Bio-Genes (India) Limited has reported Consolidated financial results for the period ended March 31, 2025.
Financial Results (Q4 FY2025) - QoQ Comparison
The company has reported total income of Rs. 51.9677 crores during the period ended March 31, 2025 as compared to Rs. 36.8728 crores during the period ended December 31, 2024.
The company has posted net profit / (loss) of Rs. 1.4810 crores for the period ended March 31, 2025 as against net profit / (loss) of Rs. 2.6505 crores for the period ended December 31, 2024.
The company has reported EPS of Rs. 1.14 for the period ended March 31, 2025 as compared to Rs. 1.33 for the period ended December 31, 2024.
| Financials | Q4 FY2025 | Q3 FY2025 | % Change |
| Total Income | ₹ 51.9677 crs | ₹36.8728 crs |  40.94% |
| Net Profit | ₹1.4810 crs | ₹2.6505 crs |  -44.12% |
| EPS | ₹1.14 | ₹1.33 | -14.29% |
Financial Results (Q4 FY2025) - YoY Comparison
The company has reported total income of Rs. 51.9677 crores during the period ended March 31, 2025 as compared to Rs.43.0380 crores during the period ended March 31, 2024.
The company has posted net profit / (loss) of Rs.1.4810 crores for the period ended March 31, 2025 as against net profit / (loss) of Rs.2.6187 crores for the period ended March 31, 2024.
The company has reported EPS of Rs.1.14 for the period ended March 31, 2025 as compared to Rs.1.87 for the period ended March 31, 2024.
| Financials | Q4 FY2025 | Q4 FY2024 | % Change |
| Total Income | ₹ 51.9677 crs | ₹43.0380 crs | 20.75% |
| Net Profit | ₹1.4810 crs | ₹2.6187 crs | -43.45% |
| EPS | ₹1.14 | ₹1.87 | -39.04% |
Financial Results (Year Ended FY2025) - YoY Comparison
The company has reported total income of Rs.364.9082 crores during the Financial Year ended March 31, 2025 as compared to Rs.332.6249 crores during the Financial Year ended March 31, 2024.
The company has posted net profit / (loss) of Rs.38.5998 crores for the Financial Year ended March 31, 2025 as against net profit / (loss) of Rs.39.6185 crores for the Financial Year ended March 31, 2024.
The company has reported EPS of Rs.20.14 for the Financial Year ended March 31, 2025 as compared to Rs.21.34 for the Financial Year ended March 31, 2024.
| Financials | Year Ended FY2025 | Year Ended FY2024 | % Change |
| Total Income | ₹364.9082 crs | ₹332.6249 crs | 9.71% |
| Net Profit | ₹38.5998 crs | ₹39.6185 crs | -2.57% |
| EPS | ₹20.14 | ₹21.34 | -5.62% |
Shares of Nath Bio-Genes (India) Limited was last trading in BSE at Rs. 157.50 as compared to the previous close of Rs. 156.65. The total number of shares traded during the day was 364 in over 35 trades.
The stock hit an intraday high of Rs. 170.00 and intraday low of 157.30. The net turnover during the day was Rs. 57488.00.
